文献速递神经免疫脑血管病神经重症与神经感染

结节病性神经病复发相关因素的多中心回顾性队列研究

Factors Associated With Relapse in Patients With Neurosarcoidosis.
PubMed 文献 · Neurology · 2025-05-15

该多中心回顾性队列纳入174例可能的、很可能的或确诊的结节病性神经病患者,中位随访24个月,分析复发预测因素。脑实质病变、脑脊液寡克隆带阳性、脑脊液葡萄糖<40 mg/dL及脑脊液蛋白≥1,000 mg/dL为复发风险因素,风险因素数量越多复发越早且治疗升级比例越高。

要点

  • 脑实质病变、脑脊液寡克隆带、低脑脊液葡萄糖及高脑脊液蛋白是复发风险因素。
  • 3-4个风险因素患者中位无复发生存期12个月,显著短于1-2个风险因素者36个月。
  • 风险因素数量越多,临床实践中治疗升级的可能性越高。

核心结论

  • 识别脑实质病变、脑脊液寡克隆带、脑脊液葡萄糖<40 mg/dL和脑脊液蛋白≥1,000 mg/dL有助于预后判断并可能指导个体化治疗。
  • 多个风险因素并存提示复发风险更高,可能需要更积极的治疗。

研究设计与样本

  • 多中心回顾性队列研究,纳入2010年1月1日至2024年6月30日欧洲6个三级神经免疫中心诊断的174例可能、很可能或确诊的结节病性神经病患者。
  • 中位随访24个月(四分位距12-48.8),平均年龄48.1岁,女性占57.5%。

主要发现

  • CNS实质病变(包括脑炎、脊髓炎和视神经炎)与复发风险相关(HR 2.3,95% CI 1.3-4.2)。
  • 脑脊液特异性寡克隆带阳性与复发风险相关(HR 2.1,95% CI 1.3-3.6)。
  • 脑脊液葡萄糖<40 mg/dL与复发风险相关(HR 2,95% CI 1.1-3.4)。
  • 脑脊液蛋白≥1,000 mg/dL与复发风险相关(HR 2.1,95% CI 1.3-3.5)。
  • 3-4个风险因素患者中位无复发生存期12个月(95% CI 4.3-19.7),1-2个风险因素者36个月(95% CI 24.3-47.7),无风险因素者120个月(95% CI 2.1-237.9)(p < 0.01)。

关键数值与推荐

  • 复发定义为初始表现后≥2个月随访时出现临床复发或进展,或新发MRI病灶。
  • 治疗升级可能性随风险因素数量增加:无风险因素者14.3%,1-2个风险因素者28.2%,3-4个风险因素者50%(p < 0.01)。

临床怎么用

  • 对结节病性神经病患者应评估脑实质病变、脑脊液寡克隆带、脑脊液葡萄糖和蛋白水平以进行风险分层。
  • 存在多个风险因素的患者复发风险高,可考虑更积极的治疗策略。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 样本量174例,部分亚组分析可能受限。
  • 随访时间中位24个月,长期复发风险未完全评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Five to 10 percent of patients with sarcoidosis show involvement of the nervous system. Given the serious nature of neurosarcoidosis and the high risk of irreversible neurologic damage, rapid diagnosis, accurate prognostication, and individualized treatment are crucial. The aim of this study was to identify factors associated with relapses in neurosarcoidosis. METHODS: In this multicenter retrospective cohort study, patients diagnosed with possible, probable, or definite neurosarcoidosis between January 1, 2010, and June 30, 2024, at 6 tertiary neuroimmunology centers across Europe were included. Patients were identified from the respective hospital-based databases by the participating centers. Clinical presentation, imaging results, CSF analysis, and immunosuppressive therapies were evaluated. Predictors of relapse, defined as clinical relapse or progression, or new MRI lesions on follow-up ≥2 months after initial manifestation, were analyzed with log-rank tests and Cox regression models, and therapeutic strategies in clinical practice were assessed. The association between identified risk factors (RFs) and therapeutic strategies was explored. RESULTS: A total of 174 patients with neurosarcoidosis were included with a median follow-up of 24 months (interquartile range 12-48.8). The mean age was 48.1 years, and 57.5% were female. CNS parenchymal lesions including encephalitis, myelitis, and optic neuritis (hazard ratio [HR] 2.3, 95% CI 1.3-4.2); CSF-specific oligoclonal bands (OCBs) (HR 2.1, 95% CI 1.3-3.6); CSF glucose <40 mg/dL (HR 2, 95% CI 1.1-3.4); and CSF protein ≥1,000 mg/dL (HR 2.1, 95% CI 1.3-3.5) were identified as RFs of relapse. Patients with 3-4 RFs had a median relapse-free survival of 12 months (95% CI 4.3-19.7), compared with 36 months (95% CI 24.3-47.7) in patients with 1-2 RFs and 120 months (95% CI 2.1-237.9) in patients without RFs (p < 0.01). The likelihood of treatment escalation increased with the number of RFs, from 14.3% in patients without RFs to 28.2% and 50% in patients with 1-2 or 3-4 RFs, respectively (p < 0.01). DISCUSSION: The identification of specific RFs, including parenchymal lesions, OCBs, CSF glucose <40 mg/dL, and CSF protein ≥1,000 mg/dL, enables better prognostication and might inform individualized treatment approaches. Patients with multiple RFs are at greater risk of relapse, possibly suggesting the need for more aggressive therapies.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Nitsch L, Skowasch D, Courtin E, et al. Factors Associated With Relapse in Patients With Neurosarcoidosis. Neurology. 2025. PMID: 40373242. doi:10.1212/WNL.0000000000213705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。